Esomeprazole Pediatric Dose — Gastrointestinal System
Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly blocking the H⁺/K⁺-ATPase enzyme on the parietal cell surface. It is used in pediatric patients for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and related acid-peptic conditions. Both intravenous and oral formulations are available, allowing flexible administration across care settings.
Pediatric Dosing
Dosing is stratified by weight band. The maximum total daily dose is 80 mg divided BID regardless of weight category.
| Weight Band | Dose | Frequency | Route |
|---|---|---|---|
| < 10 kg | 0.5–1 mg/kg/day | Once daily; may increase to twice daily | IV or PO |
| 10–20 kg | 10 mg/dose | Once daily; may increase to twice daily (max 10 mg/dose) | IV or PO |
| > 20 kg | 1 mg/kg/day | Once daily | IV or PO |
Worked examples:
- 7 kg child (<10 kg): 0.5–1 mg/kg/day × 7 kg = 3.5–7 mg/day; may divide into twice-daily dosing if clinically indicated.
- 15 kg child (10–20 kg): 10 mg once daily; may increase to 10 mg twice daily if needed.
- 25 kg child (>20 kg): 1 mg/kg/day × 25 kg = 25 mg/day; maximum 80 mg/day divided BID.
Indications and Clinical Context
Esomeprazole is indicated in pediatric patients for the management of GERD and erosive esophagitis. It is appropriate when acid suppression is required beyond the scope of H₂-receptor antagonists, particularly in patients with documented esophagitis or refractory reflux symptoms. Its use is consistent with standard gastroenterology guidelines for pediatric acid-peptic disease.
The intravenous formulation is particularly useful in hospitalized or NPO patients who require continued acid suppression. Oral therapy is preferred for outpatient or step-down management. Dose escalation to twice-daily dosing should be guided by clinical response and tolerability.
Administration and Monitoring
Esomeprazole may be administered intravenously or orally depending on the clinical setting. IV doses should be given as an infusion per institutional protocol; consult institutional protocol for specific infusion duration and compatible diluents. Oral capsules may be opened and granules mixed with water or applesauce for younger children unable to swallow intact capsules. Administer oral doses ideally 30–60 minutes before a meal for optimal efficacy.
- Maximum dose: 80 mg/day divided BID (all weight categories).
- Adverse effects to monitor: headache, nausea, diarrhea, abdominal pain; with prolonged use, monitor for hypomagnesemia and potential impact on bone density.
- Contraindications/precautions: hypersensitivity to esomeprazole or other PPIs; caution with CYP2C19-metabolized drugs (e.g., clopidogrel).
- Dose adjustments for hepatic impairment may be required; consult institutional protocol.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.